GeNeuro SA chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A€ (N/A)
Beta 0.41
Market capitalization 65.83M
Operating cash flow N/A
ESG Scores unknown

Company description

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -5.25M -4.08M -707.2k 37k
Total Cashflows From Investing Activities -76.9k -46.4k -22.8k -43.6k
Net Borrowings 7.18M 7.18M -342.8k -230.3k
Total Cash From Financing Activities 37.6k 6.94M 8.15M 5.38M
Change To Operating Activities -5.4M 2.69M 254.6k -507k
Issuance Of Stock 37.6k 10M 10M 6.02M
Net Income -8.33M -9.46M -8.96M -6.82M
Change In Cash -17.64M -3.03M 911.5k -1.36M
Effect Of Exchange Rate -71.9k -26.8k -40.9k 74.1k
Total Cash From Operating Activities -17.53M -9.89M -7.17M -6.77M
Depreciation 55k 346.7k 353.6k 290.3k
Change To Account Receivables
Other Cashflows From Financing Activities -249k -249k -1.43M -414.7k
Change To Netincome 1.38M 603.1k 1.88M 216.7k
Capital Expenditures -30.5k -50.4k -21.4k -40.4k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 10.67M 5.22M 4.12M 3.66M
Income Before Tax -8.33M -9.46M -8.96M -6.82M
Net Income -8.33M -9.46M -8.96M -6.82M
Selling General Administrative 4.92M 3.76M 3.3M 2.68M
Gross Profit 7.46M
Ebit -8.09M -8.99M -8.82M -6.83M
Operating Income -8.09M -8.99M -8.82M -6.83M
Interest Expense -441.9k -441.9k -72.3k
Income Tax Expense
Total Revenue 7.46M
Cost Of Revenue
Total Other Income ExpenseNet -239.2k -470.6k -138.8k 15.2k
Net Income From Continuing Ops -8.33M -9.46M -8.96M -6.82M
Net Income Applicable To Common Shares -8.33M -9.46M -8.96M -6.82M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 8.5M 14.61M 5M 7.69M
Total Stockholder Equity 5.55M -5.21M 5.51M 4.85M
Other Current Liabilities 47.1k 191.6k 9.2k 496.9k
Total Assets 14.05M 9.4M 10.51M 12.54M
Common Stock 614.7k 614.7k 892.3k 972k
Other Current Assets 448.2k 202.3k 130.5k 3.15M
Retained Earnings -47.98M -57.43M -52M -58.2M
Treasury Stock -783.1k -2.04M 41.92M 41.83M
Cash 8.96M 5.93M 6.84M 5.48M
Total Current Liabilities 6.38M 10.98M 2.33M 3.07M
Other Stockholder Equity -783.1k -2.04M 42.69M 42.56M
Property, Plant, and Equipment 100.7k 677.5k 1.44M 1.22M
Total Current Assets 12.45M 7.28M 7.66M 9.87M
Net Tangible Assets 4.39M -6.36M 4.37M 3.7M
Net Receivables 2.63M 974.8k 609.1k 1.17M
Accounts Payable 5.43M 1.25M 540.4k 581.4k


Insider Transactions

Here are the insider transactions of stock shares related to GeNeuro SA:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to GeNeuro SA. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on GeNeuro SA

Here is the result of two systematic investment strategies applied to GeNeuro SA. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on GeNeuro SA

The following chart shows the equity curve of the two systematic investment strategies applied to GeNeuro SA:

GeNeuro SA automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 4.85% on the backtest period.

Performance at glance

Performance

4.85 %

Latent gain

24.26 €

Invested capital

500.7 €

Annualized return

6.55 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on GeNeuro SA

This is the result of two momentum investment strategies applied to GeNeuro SA. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on GeNeuro SA

The following chart shows all the entries opened by the momentum investment system on GeNeuro SA:

GeNeuro SA momentum entries
  • The first momentum investment strategy would give -1.81% of return on GeNeuro SA. That represents -13.61€ of latent gain with 750.87€ of employed capital.
  • The second momentum investment strategy would give 0.39% of return on GeNeuro SA. That represents 1.95€ of latent gain with 499.85€ of employed capital.
Performance at glance (1Q Momentum)

Performance

-1.81 %

Latent gain

-13.61 €

Invested capital

750.87 €

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0.39 %

Latent gain

1.95 €

Invested capital

499.85 €

Annualized return

1.5 %

Momentum equity curve on GeNeuro SA

The following chart shows the equity curve of the two momentum strategies applied to GeNeuro SA:

GeNeuro SA momentum equity

Note: the dividends potentially given by GeNeuro SA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on GeNeuro SA

The following chart shows the employed capital evolution of the two momentum strategies on GeNeuro SA since the beginning:

GeNeuro SA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on GeNeuro SA

Buy the dip entry openings on GeNeuro SA

GeNeuro SA

The performance achieved by the robo-advisor on GeNeuro SA is 0%. That represents 0.0$ of latent gain with 0.0€ of employed capital. The following chart shows GeNeuro SA stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of GeNeuro SA, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 €

Invested capital

0.0 €

Annualized return

-0.0 %

Equity curve of the strategy applied to GeNeuro SA

The following chart shows the result of the investment strategy applied to GeNeuro SA:

GeNeuro SA

Note: the dividends potentially given by GeNeuro SA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on GeNeuro SA

The following chart shows the employed capital evolution since the beginning of the investment strategy on GeNeuro SA:

GeNeuro SA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on GeNeuro SA

In this section, I will compare the three previous investment strategies applied to GeNeuro SA.

Equity curve comparison on GeNeuro SA

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

GeNeuro SA investment strategy comparison

Employed capital comparison on GeNeuro SA

GeNeuro SA investment comparison

Performance comparison on GeNeuro SA

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 4.85% 24.26€ 500.7€ 6.55%
Momentum 1 quarter -1.81% -13.61€ 750.87€ -3.62%
Momentum 2 quarters 0.39% 1.95€ 499.85€ 1.5%
Non-directional 0% 0.0€ 0.0€ -0.0%
Annualized return comparison

Automatic investment

6.55 %

Momentum 1Q

1.5 %

Momentum 2Q

1.5 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with GeNeuro SA:

Positive correlations

Most correlated stocks this year

  • GeNeuro SA

  • Most correlated stocks last 3 months

  • GOLDEN RES DEV
  • Predilife S.A
  • WANJIA GROUP
  • CLP HOLDINGS
  • GeNeuro SA

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between GeNeuro SA and the other stocks. There may be false positives or some missing correlated stocks. If the price of GeNeuro SA does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name GeNeuro SA
    Country Switzerland
    City Plan-les-Ouates
    Address 3 chemin du PrE-Fleuri
    Phone 41 22 552 48 00
    Website www.geneuro.com
    FullTime employees 16
    Industry Biotechnology
    Sector Healthcare
    Exchange XPAR
    Ticker GNRO.XPAR
    Market www.euronext.com

    GeNeuro SA ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown